Richard Gaster
Managing Partner @ venBio Partners
San Francisco, United States
Richard Gaster is a Series B investor at venBio Partners in San Francisco focused on Biotechnology and Biopharma. Richard S. Gaster is based out of San Francisco, California and is the Managing Partner of venBio Partners. Richard previously worked at Alumis as a Board Member. Richard S. Gaster attended the Stanford University School of Medicine. Richard S. Gaster has been named to Forbes “30 Under 30” in Science and Healthcare.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 59%
Last updated:
For AI agents: llms.txt
Industries Richard Gaster invests in
Stages Richard Gaster invests in
Countries Richard Gaster invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 10 (59%)
- Biopharma 7 (41%)
- Life Science 5 (29%)
- Health Care 4 (24%)
- Pharmaceutical 4 (24%)
Stage
- Series B 7 (41%)
- Series A 5 (29%)
- Series C 3 (18%)
- Post-IPO Equity 1 (6%)
Country
- United States 9 (53%)
- Switzerland 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Oak hill bio
|
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines. | $32.5M / Series A / Jun 01, 2026 | |
Aeovian Pharmaceuticals
|
Aeovian Pharmaceuticals develops and investigates targeted small molecule therapeutics aimed at restoring cellular metabolic quality control to address dysregulated growth and signaling linked to certain rare genetic and age-related conditions. The company’s pipeline centers on compounds that selectively modulate specific biological pathways,including inhibitors designed to influence disease processes associated with neurological dysfunction. Its lead development candidate is a central nervous system-penetrant selective inhibitor being evaluated in clinical trials for refractory seizures related to a genetic disorder, and additional compounds are in earlier stages of investigation for other disease areas. Aeovian Pharmaceuticals also maintains a portfolio of proprietary molecules that engage defined molecular targets to explore potential treatments beyond its program. | $55M / Series B / Dec 16, 2025 | |
Alumis
|
Alumis is a precision medicines company looking to eliminate the “all-comers” approach that is seen with today’s treatments for people with autoimmune disease. Even with the innovation of the last decade, many patients continue to cycle through the approved therapies while continuing to look for the right therapy to alleviate the impact of theirdisease without life-impacting side effects. Esker leverages a precision analytics platform, powered by Foresite Labs, coupled with a team of experts with deep experience in precision medicine drug development and immunology, in order to create medicines that change the lives of people with autoimmune disease. | $259M / Series C / Mar 06, 2024 | |
Attralus
|
Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients with systemic amyloidosis. Its proprietary peptide-based pan-amyloid targeting agents have the potential to diagnose and treat all forms and stages of systemic amyloidosis. The company is focused on targeting common pathology inall systemic amyloidosis diseases, with the goal of developing treatments for all subtypes of amyloidosis, including the majority in which there are currently no treatment options. | $56M / Series B / Feb 06, 2024 | |
Pharvaris
|
Pharvaris is a clinical-stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients. By targeting this clinically proven therapeutic target with novel small molecules, we are progressing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other B2 receptor-mediated indications.PHA121, Pharvaris’ lead drug candidate, is a novel and potent small-molecule bradykinin B2 receptor antagonist currently under Phase 1 clinical study.The co-founders of Pharvaris include an inventor of icatibant and the leadership from Jerini AG that developed icatibant for the treatment of HAE, now sold by Takeda under the brand name Firazyr®. | $70M / Post-IPO Equity / Jun 20, 2023 | |
Entact Bio
|
Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function. It was founded by a team with deep roots in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development. The company's proprietary EncompassTM platform was designed tocreate enhancement-targeting chimeric (ENTACTM) medicines. ENTACs take advantage of DUBs' ability to regulate proteins. | $81M / Series A / Dec 06, 2022 | |
ACELYRIN
|
ACELYRIN is a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of promising drug candidates and by leveraging its expertise to rapidly advance these medicines to patients. | $300M / Series C / Sep 13, 2022 | |
ImmPACT Bio
|
ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues. | $139.9M / Series B / Jan 20, 2022 | |
|
ACELYRIN
|
ACELYRIN is a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of promising drug candidates and by leveraging its expertise to rapidly advance these medicines to patients. | $250M / Series B / Nov 16, 2021 | |
|
Attralus
|
Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients with systemic amyloidosis. Its proprietary peptide-based pan-amyloid targeting agents have the potential to diagnose and treat all forms and stages of systemic amyloidosis. The company is focused on targeting common pathology inall systemic amyloidosis diseases, with the goal of developing treatments for all subtypes of amyloidosis, including the majority in which there are currently no treatment options. | $116M / Series B / Sep 08, 2021 | |
| See all 17 investments → | |||
Co-Investors
About venBio Partners
venBio invests in promising companies at various stages: from early to late stage, and from academic startups to spinouts. We tend to lead most of our investments, and we enjoy building syndicates and teams.We are mindful of potential acquisition partners from the outset, and we ensure that our companies are best positioned to meet theirrequirements. This includes IP, CMC, and the details of clinical trials, including indication, trial design, endpoints, powering, and regulatory considerations. Our team’s expertise and involvement helps companies make a bigger impact, and this leads to impactful and lasting relationships with the leaders that we work with.
venBio Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Behzad Aghazadeh
Managing Team
|
|||
Corey Goodman
Managing Partner
|
|||
|
Richard Gaster
Managing Partner
|
|||
Robert Adelman
Managing Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Richard Gaster invest in?
Richard Gaster invests primarily in Biotechnology, Biopharma and Life Science startups, most often at Series B and Series A stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Richard Gaster?
Public channels for Richard Gaster include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Richard Gaster last invest?
The most recent investment recorded for Richard Gaster closed in Jun 2026. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
